Advancing Neurosurgical Innovations Through Mentor-Mentee Collaborations
March 11, 2024
Dr. Susan Pannullo, professor of clinical neurological surgery, considers it an honor and duty to support the next generation of neurosurgeons and help them reach their personal and professional goals. She met a like-minded mentee, Dr. Mohammed Fouda, fellow in neurological surgery. Both doctors have a keen interest in advancing neurosurgical technologies and team up to improve patient outcomes.
Conference Showcases Biomedical Innovation at the Intersection of Business and Science
March 7, 2024
The 2024 Startup Symposium & InvestConnect Conference celebrated scientific inquiry and the entrepreneurial spirit.
Structural Study Points the Way to Better Malaria Drugs
January 18, 2024
Structural insights into a potent antimalarial drug candidate’s interaction with the malaria parasite Plasmodium falciparum have paved the way for drug-resistant malaria therapies, according to a new study by researchers at Weill Cornell Medicine and Van Andel Institute.
Cross-Disciplinary Collaborations Catalyze Serial Entrepreneurship
December 19, 2023
Dr. Jason Spector, chief of the Division of Plastic and Reconstructive Surgery at Weill Cornell Medicine, is a prolific inventor and serial entrepreneur with multiple patents and a global patent portfolio. In this conversation, Dr. Spector shared with Enterprise Innovation and fellow Weill Cornell Medicine clinicians his journey of becoming a serial entrepreneur.
Parker Institute for Cancer Immunotherapy (PICI) Welcomes Weill Cornell Medicine to Cancer Research Consortium
December 13, 2023
San Francisco and New York — Dec. 13, 2023 — The Parker Institute for Cancer Immunotherapy (PICI), the largest concentration of immuno-oncology (IO) expertise in the world, announced it has added Weill Cornell Medicine to its network of preeminent academic and medical research institutions at the forefront of the fight against cancer.
Accelerating BioVenture Innovation Participants Pitch Tri-Institutional Technologies to Early-Stage Venture Capitalists
December 12, 2023
BioVenture eLab celebrated the hard work of its 2023 Accelerating BioVenture Innovation cohort with a pitch event on Dec. 6 in Uris Auditorium. The group of graduate students, postdoctoral trainees and clinicians from Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center and The Rockefeller University received 12 weeks of intense didactic instruction. They then spent three weeks putting their knowledge about intellectual property, research and development, and market research into polishing investor pitches for the Tri-I inventions that formed the basis of their experimental NewCos.
Deep Brain Stimulation Improves Cognition During Chronic Recovery Phase of Brain Injury
December 4, 2023
Five people who had life-altering, seemingly irreversible cognitive deficits following moderate to severe traumatic brain injuries showed substantial improvements in their cognition and quality of life after receiving an experimental form of deep brain stimulation (DBS) in a phase 1 clinical trial. The trial, reported Dec. 4 in Nature Medicine, was led by investigators at Weill Cornell Medicine, Stanford University, the Cleveland Clinic, Harvard Medical School and the University of Utah.
Entrepreneurial Surgeon Presents at Eclectic Convergence Summit, a Conference about Disruption, Growth, and the Power of AI
November 30, 2023
Barry J. Beck (’90), founder of Bluemercury and CEO of Evenly Technologies, talked about entrepreneurs as disrupters, those people who see targets that no one can, and have the business savvy to move their ideas forward. “Especially with AI and the information superhighway right at your fingertips, it really levels the playing field,” he said. “I feel like people think entrepreneurs are these mythological creatures, but they’re just exceedingly good risk managers.”
Building Trust and Fostering Collaborations Key to Startup Formation
November 29, 2023
One of the hardest points on the translational road “from bench to bedside” can be the point where you have to turn over your discovery to a company you’ve founded—a company whose subsequent direction you won’t fully control.
New Radiopharmaceutical Shows Antitumor Activity in Patients with Advanced Prostate Cancer
November 3, 2023
Researchers at Weill Cornell Medicine have led a phase 1 trial of a new drug that delivers potent radiation therapy directly and specifically to cancer cells in patients with advanced prostate cancer. The clinical trial showed that the “radiopharmaceutical” was well tolerated and demonstrated promising antitumor activity, according to a new study published on Nov. 2 in the Journal of Clinical Oncology.